Scope and Principle
Section 1 establishes that Annex 1 applies to the manufacture of all sterile medicinal products and, critically for cannabis manufacturers, introduces the Contamination Control Strategy requirement that applies to all medicinal product manufacturers.
- Annex 1 applies to sterile medicinal product manufacture — most cannabis products are non-sterile and are not subject to the full Annex 1 requirements
- However, the CCS requirement in Clause 4.4 applies to all medicinal product manufacturers, including non-sterile cannabis operations
- The 2022 revision significantly expanded and updated requirements compared to the 2008 version — facilities that last reviewed Annex 1 compliance before 2022 should conduct a full gap assessment
Principle of the Quality System
Section 2 restates the Annex 1 manufacturing principle: sterile medicinal products must be manufactured under conditions designed to minimise the risks of microbial, particulate and pyrogen contamination.
- The contamination control principle requires a proactive, risk-based approach — not a reactive one
- Personnel, premises, equipment and procedures must collectively demonstrate contamination control
- The Quality System must be designed to support contamination control — not just document it
Premises
Section 3 covers cleanroom design, classified zones, pressure cascades, surfaces, drainage and the physical infrastructure supporting contamination control.
- Classified zone design must support unidirectional material and personnel flows
- Pressure cascade from higher to lower classification must be continuously monitored with documented alarm set-points
- Surface finishes must be smooth, cleanable and resistant to disinfectants — no ledges, joints or crevices accumulating contamination
- Smoke studies required under in-operation conditions with maximum intended personnel — at-rest studies alone are insufficient
Contamination Control Strategy
The most important new section for cannabis manufacturers. Clause 4.4 requires a formal, documented CCS for all medicinal product manufacturers. This is not optional and will be requested at inspection.
- The CCS must identify all contamination sources, routes and controls across the facility
- A risk assessment (typically FMEA) must underpin the CCS
- The CCS must be reviewed when changes occur and at defined periodic intervals
- Cannabis-specific contamination risks must be addressed: microbiological risk from plant material, THC/CBD cross-contamination, solvent residues, mycotoxin risk, CBN formation
- The ECI CCS template (available at documentation.html) is Annex 1 (2022) compliant
Personnel
Section 5 sets out personnel requirements including numbers, training, health surveillance, gowning qualification and behaviour in classified areas.
- Maximum personnel numbers in classified areas must be defined and validated by smoke studies
- Gowning must be qualified — not just described in a procedure
- Personnel health controls must include exclusion criteria for conditions causing excessive shedding
- Training must be role-specific, competency-assessed and documented — completion of training is not the same as competency
Equipment
Section 6 covers equipment design, qualification, installation, cleaning and maintenance in classified areas.
- Equipment installed in classified areas must be designed to be cleanable — no crevices, dead legs or inaccessible surfaces
- All equipment must be qualified (IQ/OQ/PQ) before use in GMP operations
- Cleaning of product-contact equipment must be validated with health-based acceptance limits
Utilities
Section 7 covers HVAC, purified water, compressed gases and other utility systems supporting classified manufacturing.
- HVAC must achieve and maintain classified zone specifications for particle count, temperature, humidity and air changes per hour
- HEPA filter integrity testing required annually minimum
- Compressed gases used in product-contact operations must be qualified at the point of use
- For cannabis: nitrogen blanketing of extract storage requires utility qualification and continuous oxygen monitoring
Production and Specific Technologies
Section 8 covers manufacturing in classified areas including RABS and isolator technology for aseptic operations — primarily relevant to cannabis operators manufacturing sterile preparations.
- RABS and isolator requirements are substantially expanded in the 2022 revision
- For non-sterile cannabis manufacturing, Section 8 is less directly applicable
- Any cannabis product intended for parenteral administration requires full compliance with Section 8 RABS/isolator requirements
Environmental and Process Monitoring
Section 9 is one of the most detailed and practically important sections for cannabis manufacturers — covering EM programme design, alert and action limits, sampling locations, frequencies and excursion management.
- Alert and action limits must be derived from facility-specific EMPQ baseline data — not from grade limit tables
- Sampling locations must be risk-justified, including worst-case locations identified from smoke studies
- Active air sampling, settle plates and surface contact plates each have specific requirements
- Excursion management: action limit excursion requires deviation, batch impact assessment and QP notification on the same day
- Trending of EM data is required — not just monitoring against limits
Quality Control
Section 10 covers QC testing requirements including environmental monitoring testing, sterility testing and bioburden determination.
- Microbiological methods must be validated for the organisms expected in the manufacturing environment
- Out-of-specification EM results require formal OOS investigation — not just re-testing
- For cannabis: microbiological specifications must be appropriate for the route of administration (oral vs inhalation limits differ substantially)
Glossary
The 2022 revision introduced a comprehensive glossary of defined terms — an important reference for audit responses and procedure drafting.
- Defined terms in the glossary must be used consistently throughout quality system documentation
- Key definitions relevant to cannabis manufacturing: Contamination Control Strategy, Environmental Monitoring Programme Qualification, in-operation conditions, worst-case conditions
- Where procedures or specifications use terms defined in the Annex 1 glossary, the definitions must match
Implementation and Transition
The 2022 revision entered into force August 2023 after a one-year transition period from August 2022 publication. All facilities manufacturing medicinal products were expected to be fully compliant by August 2023.
- All Annex 1 (2022) requirements are now in effect — the transition period has ended
- Facilities inspected after August 2023 will be assessed against the 2022 version
- Priority implementation areas for cannabis manufacturers: CCS (Clause 4.4), in-operation smoke studies, EMPQ-derived EM limits, gowning qualification
ECI offers Contamination Control Strategy development, gap assessments against Annex 1 (2022) and inspection preparation services for pharmaceutical cannabis manufacturers.